The world of biotech wearables is changing and evolving at warp speed in 2017, and Fisher Wallace Laboratories is at the forefront with a medical device which treats depression, anxiety and insomnia without drugs. The device has been FDA cleared for these indications since 1991 and is sold internationally. Their new OTC product, KORTEX, launching in December is designed to be a tech wearable used in conjunction with virtual reality, the first medical device to be used in a combined manner.
Chip Fisher will explain the evolution of wearables and technology for the treatment of mental health disorders, and explain the technical origins of cranial electrotherapy stimulation, the alternating current version which Fisher Wallace Laboratories has developed.
The son of stereo pioneer Avery Fisher, Charles Fisher earned his BA from Harvard university in 1978. After graduation, he worked for IBM in the Data Processing Division. He later founded and sold several companies before founding Fisher Wallace Labs in 2006 with the late Martin Wallace, PhD. Chip serves on the board of the Avery Fisher Artists Program and the Virtual Music Academy. He resides in New York City.
In late 2001, entrepreneur Charles Fisher and Dr. Martin Wallace, PhD, Cad, discovered a poorly marketed yet effective, FDA-sanctioned medical device that treats depression, anxiety, stress and insomnia without drugs or side effects: the LISS Cranial Stimulator. At that juncture, Wallace had been unable to find any means of successfully treating the acute depression he was experiencing in the aftermath of 9/11, during which he spent eight hours trapped in a building at Ground Zero. The LISS Cranial Stimulator successfully alleviated Wallace’s depression. In 2006, Fisher and Wallace purchased the patents to the device from Dr. Saul Liss, including the radio frequencies that cause the brain to produce serotonin and dopamine and lower cortisol levels. The device was then renamed the Fisher Wallace Cranial Stimulator. Dr. Saul Liss passed away in June, 2006 at the age of 84, as did Wallace in 2009. Today Fisher Wallace Laboratories continues their work and is involved in ground-breaking research at Harvard Medical School, Columbia Medical School, Massachusetts General Hospital, NYU Medical Center, and the University of Medicine and Dentistry of New Jersey.